Presented at Molecular Medicine Tri-Conference 2017, this presentation provides an overview of how genomics-based assays can be effectively implemented for immuno-oncology clinical research. With the expansion of immuno-oncology pipelines over the last decade, genomics-based assays can help design and execute smarter trials. Self-recognition HLA and KIR typing, immune gene signature, and tumor characterization can be used to develop "virtual panels" of expression targets to recapitulate IO targeted panels, identify neo-antigens directly from RNA sequencing data, and more. 

Download this presentation to learn more. Q² Solutions offers a range of genomic services to support drug discovery, precision medicine and clinical development. Our industry-leading genomic services team can help you uncover valuable insights from your genomic data. Through carefully orchestrated analyses, we work with you to choose platforms and assays that will distinctly fit your needs, and then use them to deliver valuable, informative data.

Speaker:
Victor Weigman, Ph.D., Director, Translational Genomics